Ohnaga Takashi, Shimada Yutaka, Takata Koji, Obata Tsutomu, Okumura Tomoyuki, Nagata Takuya, Kishi Hiroyuki, Muraguchi Atsushi, Tsukada Kazuhiro
Central Research Laboratories, Toyama Industrial Technology Center, Takaoka, Toyama 933-0981, Japan.
Department of Nanobio Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Mol Clin Oncol. 2016 Apr;4(4):599-602. doi: 10.3892/mco.2016.734. Epub 2016 Jan 19.
The present study evaluated the capture efficiency of esophageal and breast cancer cells with a modified 'polymeric circulating tumor cells (CTC)-chip' microfluidic device, which was developed for the isolation of circulating tumor cells. Esophageal cancer cell lines KYSE150, KYSE220 and KYSE510, and breast cancer cell lines MCF7, SKBR3 and MDA-MB-231 were used for evaluation. The capture efficiencies of the esophageal cancer cell lines in phosphate-buffered saline (PBS) were ~0.9, irrespective of epithelial cell adhesion molecule (EpCAM) expression, which was represented as the mean fluorescent intensity from 528 to 76. In the breast cancer cell lines, efficient capture was observed for MCF7 and SKBR3 in PBS; however, a low value of ~0.1 was obtained for MDA-MB-231. Fluorescent imaging of immunolabeled cells revealed marginal EpCAM expression in MDA-MB-231. Using whole blood, no clogging occurred in the microstructure-modified CTC-chip and efficiency of capture was successfully evaluated. Capture efficiencies for KYSE220 and MCF7 in whole blood were >0.7, but were of either equal or lesser efficiency in comparison to PBS. Therefore, the modified CTC-chip appears useful for clinical application due to its cost, practicality of use, and efficient cancer cell capture.
本研究使用一种改良的“聚合物循环肿瘤细胞(CTC)芯片”微流控装置评估食管癌细胞和乳腺癌细胞的捕获效率,该装置是为分离循环肿瘤细胞而开发的。使用食管癌细胞系KYSE150、KYSE220和KYSE510,以及乳腺癌细胞系MCF7、SKBR3和MDA-MB-231进行评估。食管癌细胞系在磷酸盐缓冲盐水(PBS)中的捕获效率约为0.9,与上皮细胞粘附分子(EpCAM)表达无关,EpCAM表达以528至76的平均荧光强度表示。在乳腺癌细胞系中,观察到MCF7和SKBR3在PBS中能有效捕获;然而,MDA-MB-231的捕获效率较低,约为0.1。免疫标记细胞的荧光成像显示MDA-MB-231中EpCAM表达微弱。使用全血时,微结构改良的CTC芯片未发生堵塞,并且成功评估了捕获效率。KYSE220和MCF7在全血中的捕获效率>0.7,但与PBS相比,效率相同或更低。因此,改良的CTC芯片因其成本、使用的实用性和高效的癌细胞捕获能力,似乎对临床应用有用。